Johnson & Johnson’s single-dose COVID-19 vaccine has received an accelerated approval in India for use in those 18 years and above. Its addition to the country’s arsenal comes as a relief as the viral vector vaccine has been found effective against the dreaded Delta variant that continues to circulate after taking a huge toll in the second wave.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?